Samsung Pharm Asset Resilience Ratio
Samsung Pharm asset resilience ratio. Samsung Pharm (001360) has an Asset Resilience Ratio of 6.69% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Samsung Pharm defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Samsung Pharm (2015–2024)
Asset resilience ratio of Samsung Pharm from 2015 to 2024. This chart shows how Samsung Pharm's Asset Resilience Ratio has changed over time. Read Samsung Pharm total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Samsung Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Samsung Pharm's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩15.00 Billion | 6.69% |
| Total Liquid Assets | ₩15.00 Billion | 6.69% |
Asset Resilience Insights
- Limited Liquidity: Samsung Pharm maintains only 6.69% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Samsung Pharm Industry Peers by Asset Resilience Ratio
Compare Samsung Pharm's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Samsung Pharm Asset Resilience Ratio by Year (2015–2024)
Samsung Pharm asset resilience ratio by year from 2015 to 2024. The table below shows the annual Asset Resilience Ratio data for Samsung Pharm.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.34% | ₩3.00 Billion ≈ $2.03 Million |
₩128.45 Billion ≈ $87.05 Million |
-14.63pp |
| 2022-12-31 | 16.96% | ₩20.00 Billion ≈ $13.55 Million |
₩117.91 Billion ≈ $79.91 Million |
-9.37pp |
| 2021-12-31 | 26.33% | ₩38.30 Billion ≈ $25.96 Million |
₩145.46 Billion ≈ $98.57 Million |
+24.89pp |
| 2020-12-31 | 1.45% | ₩2.59 Billion ≈ $1.75 Million |
₩178.73 Billion ≈ $121.12 Million |
-14.58pp |
| 2019-12-31 | 16.03% | ₩27.02 Billion ≈ $18.31 Million |
₩168.53 Billion ≈ $114.21 Million |
-10.47pp |
| 2018-12-31 | 26.50% | ₩42.57 Billion ≈ $28.85 Million |
₩160.65 Billion ≈ $108.87 Million |
+8.42pp |
| 2017-12-31 | 18.08% | ₩27.88 Billion ≈ $18.89 Million |
₩154.19 Billion ≈ $104.50 Million |
+13.01pp |
| 2016-12-31 | 5.08% | ₩7.02 Billion ≈ $4.76 Million |
₩138.28 Billion ≈ $93.71 Million |
-4.91pp |
| 2015-12-31 | 9.99% | ₩13.01 Billion ≈ $8.81 Million |
₩130.22 Billion ≈ $88.25 Million |
-- |
About Samsung Pharm
SAMSUNG PHARM. Co., LTD. manufactures and sells pharmaceutical products in South Korea. It offers prescription medicines, such as anticancer immunotherapy, antipyretic analgestic and antiinflammatory, antiobesity, hypotensive, antiarteriosclerotic, digestive organs, antophlegms, enzymes, ostepoposis, and transfusion agents, as well as skeletal muscle relaxants, anti-spastic, enzyme, mixed vitamin… Read more